亚辉龙(688575) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between 20 million and 30 million yuan, a decrease of 27.15 million to 28.15 million yuan compared to the previous year, representing a year-on-year decline of 90.05% to 93.37%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 65 million and 85 million yuan, down by 20.23 million to 22.23 million yuan from the previous year, reflecting a year-on-year decrease of 70.42% to 77.38%[2] - The company's net profit for 2024 was 301.53 million yuan, and the net profit after deducting non-recurring gains and losses was 287.33 million yuan[3] - The decline in performance is attributed to reduced domestic market demand due to industry policies, leading to decreased operating revenue and gross margin[4] - The company has communicated with its auditing firm regarding the earnings forecast, with no significant discrepancies reported[7] Product Development and Certification - The company has expanded its domestic chemiluminescence product menu to 180 items by the end of 2025, including a complete solution for thrombus detection[5] - The company has achieved full coverage of IVDR CE Class D certification for its preoperative series of eight chemiluminescence test reagents[5] - The company has successfully obtained a national patent for an anti-Nephrin antibody detection kit and its methods[5] Industry Recognition and Standards - The company has been recognized as a national manufacturing single champion in the field of autoimmune disease diagnostics[6] - The company is actively involved in drafting national standards for automated sample processing systems, promoting standardization in laboratory automation[6]